

## REVIEW ARTICLE OPEN



## p63: a crucial player in epithelial stemness regulation

Yanan Li<sup>1,2</sup>, Sara Giovannini<sup>1</sup>, Tingting Wang<sup>2</sup>, Jiankai Fang<sup>2</sup>, Peishan Li<sup>2</sup>, Changshun Shao<sup>2</sup>, Ying Wang<sup>3</sup> and , TOR centre\*, Yufang Shi<sup>2,✉</sup>, Eleonora Candi<sup>1,4,✉</sup>, Gerry Melino<sup>1,✉</sup> and Francesca Bernassola<sup>1,✉</sup>

© The Author(s) 2023

Epithelial tissue homeostasis is closely associated with the self-renewal and differentiation behaviors of epithelial stem cells (ESCs). p63, a well-known marker of ESCs, is an indispensable factor for their biological activities during epithelial development. The diversity of p63 isoforms expressed in distinct tissues allows this transcription factor to have a wide array of effects. p63 coordinates the transcription of genes involved in cell survival, stem cell self-renewal, migration, differentiation, and epithelial-to-mesenchymal transition. Through the regulation of these biological processes, p63 contributes to, not only normal epithelial development, but also epithelium-derived cancer pathogenesis. In this review, we provide an overview of the role of p63 in epithelial stemness regulation, including self-renewal, differentiation, proliferation, and senescence. We describe the differential expression of TAp63 and  $\Delta$ Np63 isoforms and their distinct functional activities in normal epithelial tissues and in epithelium-derived tumors. Furthermore, we summarize the signaling cascades modulating the TAp63 and  $\Delta$ Np63 isoforms as well as their downstream pathways in stemness regulation.

*Oncogene* (2023) 42:3371–3384; <https://doi.org/10.1038/s41388-023-02859-4>

## INTRODUCTION

**Structural features and expression patterns of p63**

p63 is the most ancient member belonging to the p53 family together with p73 [1–4] (Fig. 1A). All members are involved in essential biological functions, including cell death [5, 6], tumor suppression [7–10], and cell differentiation [11–14]. Its encoding gene TP63 generates two main classes of isoforms by the usage of alternative promoters. TAp63 transcripts are produced from the promoter upstream of exon 1 and transcribe for protein isoforms that contain an N-terminus acidic transactivation domain (transcriptional activation domain 1, TA1), homologous to the one of p53 (Fig. 1B). The usage of an alternative promoter located within the intron downstream of exon 3 generates transcripts encoding  $\Delta$ Np63 isoforms that lack the canonical N-terminal TA domain 1 (TA1\*). Furthermore, the TP63 gene is expressed as, at least, three alternatively spliced C-terminal isoforms ( $\alpha$ ,  $\beta$ ,  $\gamma$ ) [15]. The full-length p63 $\alpha$  proteins possess a C-terminus sterile alpha motif (SAM) domain, a protein-protein interaction domain, flanked by a second transactivation domain (TA2) and a transcription inhibitory domain (TID), which can auto-inhibit the transcriptional activity of the TA isoforms. All of the isoforms share some functional domains including the DNA-binding domain (DBD) and the oligomerization domain (OD). Altogether, the TP63 gene expresses at least six different p63 protein isoforms (TAp63 $\alpha$ , TAp63 $\beta$ , TAp63 $\gamma$ ,  $\Delta$ Np63 $\alpha$ ,  $\Delta$ Np63 $\beta$  and  $\Delta$ Np63 $\gamma$ ). Minor alpha-helix changes produce profound functional differences; accordingly, these six isoforms display distinct functions. The identification of two new C-terminus variants, p63 $\delta$  and  $\epsilon$ , has expanded the isoforms number from 6 to 10 [16, 17]. Moreover,

two additional N-terminal short splicing isoforms lacking exon 4 have been found in invasive breast carcinomas (d4TAp63 and  $\Delta$ Np73L) [18].


The TAp63 isoforms are generally expressed at low basal levels in epithelial cells, while their expression can be induced in response to DNA damage or other cellular stresses.  $\Delta$ Np63 isoforms are instead constitutively expressed in the basal compartment of the epidermis and in other epithelial tissues [19–21]. Unlike TAp63,  $\Delta$ Np63 expression is downregulated in response to genotoxic stress. TAp63 binds canonical p53-responsive elements (RE), thus activating the transcription of several p53 target genes, and therefore acting as a tumor suppressor through the regulation of cell-cycle arrest and apoptosis [16, 22–26]. Conversely, the  $\Delta$ Np63 isoform acts as an oncogene [27, 28]. The  $\Delta$ Np63 isoforms are mainly involved in maintaining the self-renewing capacity of progenitor cells in different epithelia [29–32]. TAp63 and  $\Delta$ Np63 variants are typically and differentially expressed in epithelial tissues and their appendages [33, 34]. For example,  $\Delta$ Np63 (mainly  $\Delta$ Np63 $\alpha$ ) is the most predominant isoform expressed in the skin, vagina and esophageal mucosa. Furthermore, TAp63 and  $\Delta$ Np63 isoforms are present during distinct stages of embryonic development [35]. During epidermal development, while the TAp63 variants are expressed in the uncommitted ectoderm surface, the  $\Delta$ Np63 isoforms are transcribed only after the surface ectoderm has been committed towards a stratification program [36].

**Role of p63 in ectodermal development and epithelial homeostasis**

Epithelial tissues cover external surfaces of organs and blood vessels, as well as the internal surfaces of cavities in many internal

<sup>1</sup>Department of Experimental Medicine, TOR, University of Rome Tor Vergata, 00133 Rome, Italy. <sup>2</sup>The Third Affiliated Hospital of Soochow University, Institutes for Translational Medicine, Soochow University, Suzhou 215000, China. <sup>3</sup>Shanghai Institute of Nutrition and Health, Shanghai 200031, China. <sup>4</sup>Biochemistry Laboratory, Istituto Dermopatico Immacolata (IDI-IRCCS), 00100 Rome, Italy. \*A list of authors and their affiliations appears at the end of the paper. ✉email: yfshi@suda.edu.cn; candi@uniroma2.it; melino@uniroma2.it; bernasso@uniroma2.it

Received: 31 July 2023 Revised: 26 September 2023 Accepted: 2 October 2023  
Published online: 17 October 2023



**Fig. 1 General features of p63. A** Timeline of important discoveries in the research field of p63 in epithelial tissues. **B** Schematic representation of the alternative promoters generating the TAp63 and ΔNp63 isoforms along with structural features and domains of the p63 protein variants. p63 protein are shown: TA transactivating domain, DBD DNA-binding domain, OD oligomerization domain, SAM sterile alpha motif, TID trans-inhibitory domain. **C** The differential expression pattern of TAp63 and ΔNp63 variants (α, β, and γ) in different normal tissues (Data source, GTex portal).

organs [37]. These tissues participate in a diverse range of physiological functions, including absorbing nutrients, filtering and eliminating toxic metabolic by-products, retaining body fluids, regulating body temperature and, in the case of epidermis, the outmost layer of the skin, acting as effective barriers against pathogens [38, 39]. Based on their structure and function, the epithelium can be divided into three categories: covering epithelium, glandular epithelium, and sensory epithelium. Epithelial tissue homeostasis is preserved by ESCs located within specialized niches which are responsive to the regenerative demands of the tissue [38, 40]. p63, as an indispensable transcription factor for epithelial morphogenesis and stemness [19, 20], is highly expressed in the basal or progenitor layers of various epithelial tissues [16] (Fig. 1C). As a result, p63-deficient mice lack epidermis and other stratified epithelia [20, 34]. The mice are born alive but die shortly after birth because of severe dehydration, and manifest dramatic developmental defects, affecting particularly their limbs and skin [19]. In addition, absence of p63 results in the failure of basal cell population maintenance, suggesting an essential role of p63 in the self-renewing of epithelial stem cell [41, 42]. Besides, cancerogenesis and epithelium tissue regeneration are somewhat related process sharing similar mechanisms, both involving a p63-cascaded


regulation [2, 43]. The shared mechanisms between cancerogenesis and tissue regeneration highlight the complex nature of p63-mediated processes. Understanding the intricate interplay between p63 and its downstream targets in both contexts is essential for unraveling the underlying molecular mechanisms and potentially identifying therapeutic strategies for cancer treatment and tissue regeneration.

**ROLE OF P63 IN EPITHELIAL STEM CELL BIOLOGY**

The self-renewing ability of stem cells located in the innermost basal layer is crucial for maintaining stratified epithelial tissue homeostasis, as basal cells move up and become suprabasal cells, they lose their capacity to proliferate and instead undergo a terminal differentiation program [44, 45]. Mice lacking p63 fail to develop stratified epithelia, epithelial appendages, as well as glandular tissues, indicating that p63 is required for the commitment of epithelial stem cells (ESCs) during embryonic development [29, 46–48].

**Skin**

The role of ESCs in the homeostatic maintenance of the skin and in wound repair has been well recognized. Skin epithelium,



**Fig. 2** p63 expression in the development of epidermis. **A** Schematic diagram of epidermal structure. The expression of p63, especially  $\Delta$ Np63 isoform, is higher in basal cells and decreases during the basal-to-suprabasal transition. **B** The ESC differentiation program initiates within the basal layer and generates non-stem-committed TA cells, which give rise to the progenitor population, whose progeny finally differentiates into multiple epithelium lineages. **C** The specific expression of TAp63 and  $\Delta$ Np63 in different phases during epidermal development. **D** A cross-section of the hair follicle (HF) and the surrounding epidermis, showing differential expression of p63 isoforms in various HF stem cells subsets.

also known as epidermis, is a stratified squamous epithelium (Fig. 2A). Its proliferative basal compartment consists of ESCs and their progeny, the daughter transient amplifying (TA) cells [49]. ESCs have a strong ability to self-renew to supplement senescent keratinocytes and help to promote healing. ESCs divide asymmetrically to generate a stem and a TA cell. The latter withdraws from the cell cycle and detaches from the basement membrane to begin terminal differentiation (Fig. 2B). This process occurs concomitantly with the movement of the differentiating keratinocyte toward the surface of the skin. p63 is enriched in the basal layer of the epidermis and serves as a specific marker of ESCs, in which it assists in regulating proliferation and differentiation [20, 50]. p63 expression, especially  $\Delta$ Np63, is reduced at both protein and mRNA levels during the basal-to-suprabasal transition in epidermis [51] (Fig. 2A). Furthermore, p63 expression induces hyperproliferation of ESCs, whereas, downregulation of p63 is needed for terminal differentiation to take place [52]. Epidermal progenitors with depleted p63 have impaired self-renewal potential, which could render them incapable of perpetuating [53]. In keratinocytes (precursor cell derived from ESCs), p63 expression is responsible for cell adhesion, inhibiting apoptosis, and upholding the integrity of the epidermal tissue [54].

Mice lacking  $\Delta$ Np63 display a dramatic loss of keratinocytes and exhibit single-layered surface epithelium instead of a fully stratified epidermis, perhaps, this is due to the early onset of excessive cell proliferation decline of all stem and TA cells [55, 56]. Ablating TAp63 in the germline (TAp63<sup>-/-</sup> mice) or in keratin 14 (K14)-expressing cells in the basal layer of the epidermis (TAp63<sup>fl/fl</sup>; K14Cre<sup>+</sup> animals) leads to impaired proliferation, accelerated cellular aging, and genomic instability in these precursor cells. Moreover, the mice experience premature aging, manifesting blisters formation, skin ulcerations, and impaired hair morphogenesis [57, 58]. The TAp63 isoforms are the first to be expressed during embryonic epidermal development, during which they are


necessary for the commitment to epithelial stratification. During later stages of epidermal development, a switch to  $\Delta$ Np63 isoforms is then required to counterbalance the activity of the TAp63 proteins, thereby allowing cells to respond to terminal differentiation cues [36] (Fig. 2C).

### Skin appendages

In both vertebrates and non-vertebrates, p63 plays a crucial role in the development of epithelial appendages such as hair follicles and many exocrine glands [59, 60]. Both of mice and zebrafish lacking p63 result in failure to develop epithelial appendages and other structures that arise from epithelial-mesenchymal interactions [60].

### Hair follicle

Distinct populations of stem cells located in the interfollicular epidermis and various niches of the hair follicle (HF) are responsible for maintaining the epithelium. Upon injury, the progenies of all stem cells are capable of leaving their respective niches and contributing to the wound healing process known as re-epithelialization [61–64]. In normal human HFs, p63 expression is principally restricted to cells with high proliferative potential, named HF stem cells (HFSCs) [65] (Fig. 2D). It's also a potential indicator of interfollicular epidermal stem cells (IESCs) [65], while it is absent in cells that are undergoing terminal differentiation [56, 62–64]. During its growth cycle, the HF appears to recapitulate part of its development during embryogenesis, in which p63 is involved [66]. A role for p63 in hair formation has also been well established, as p63-null mice fail to form HF [67, 68]. Furthermore,  $\Delta$ Np63 is enriched in the developing of hair placode, however, its expression is restricted to the outer root sheath, the matrix cells, and the stem cells of the HF bulge in mature hair. As reported, mice with mutant  $\Delta$ Np63 $\alpha$  exhibited a missing HFSCs niche and further overall cycling defects [69].



**Fig. 3 Stem cell in glandular and stratified epithelia.** **A** A schematic model depicting the structure of the mammary gland epithelium, composed by basal stem cells, basal myoepithelial cells, and luminal cells. **B** The model shows the distribution of basal stem cells, luminal cells, and neuroendocrine cells in the prostate gland epithelium. **C** Schematic representation of the cornea. LSCs produce daughter TA cells that migrate towards the apical layer of the central cornea, and, eventually, become terminally differentiated (arrowed).  $\Delta Np63$  is the dominant p63 isoform expressed in LSCs and its expression decreases from limbus to the central cornea. Ep epithelium, BL Bowman's layer, St stroma.

### Mammary gland

The mammary gland consists of a bilayered epithelium that is composed by an inner luminal layer of secretory epithelial cells, and an outer basal compartment of myoepithelial cells, including rare stem cells [70] (Fig. 3A). During embryonic development, sustained p63 expression in multipotent progenitors facilitates the differentiation of unipotent basal cell lineage in mammary gland [71]. TP63 null mice genetically deleted for all the isoforms, display complete lack of mammary glands [20]. Similarly, humans harboring germline p63 mutations exhibit mammary hypoplasia [72]. Subsequent studies indicated that  $\Delta Np63$  is the predominant variant governing mammary glands morphogenesis. Romano and collaborators reported that selective genetic ablation of  $\Delta Np63$  recapitulates the mammary gland defective phenotype observed in the p63 global knockout mice [73]. In the adult mammary gland,  $\Delta Np63$  and TAp63 exhibit segregated expression in mammary stem cells and progenitor cells [74, 75].  $\Delta Np63$ , especially the  $\Delta Np63\alpha$  isoform, is mainly expressed in the basal cell layer that is composed of myoepithelial and stem/progenitor cells, while its expression is maintained very low in luminal cells [76, 77]. TAp63 protein is instead expressed in luminal cells [78]. The expression of  $\Delta Np63$  in mammary progenitor cells serves to maintain their undifferentiated state and quiescence and therefore to promote stem cell activity [31, 74, 79–81]. In addition, it has been reported that  $\Delta Np63$  can reprogram adult luminal into basal cells by promoting an intermediate multipotent-like state, thus supporting the concept of reversible plasticity in epithelial cell fate [71, 82].  $\Delta Np63$  is expressed in the adult mammary gland during all the physiological stages, virgin, pregnant, lactation, and post-lactation involution states [75]. On the other hand, the mammary glands of p63<sup>+/-</sup> mice appear normal in the virgin, pregnant and lactating states.

### Prostate gland

Normal prostate epithelium contains three major epithelial cell types, basal cells (including stem and TA cells), luminal cells, and neuroendocrine cells [83] (Fig. 3B). In the adult, prostate stem cells can give rise to all three lineages of prostate epithelial cells [84]. p63 has been shown to play an essential role in normal stem cell function during prostate development. At birth, mice lacking p63 manifest prostate bud agenesis and urothelial abnormalities [4, 45]. Prostatespheres derived from p63-expressing basal cells

efficiently form organoids expressing the differentiation marker cytokeratin 18 (CK18) and a functional androgen receptor [85]. The prostate agenesis indicates that p63 is required for the formation of prostate stem cells residing in the basal layer of the primitive urogenital sinus epithelium. In the absence of p63, the epithelial lining of the urethra indeed shows lack of stratification and complete absence of basal cells [4]. p63-null blastocyst complementation experiments have demonstrated that p63-positive basal cells are necessary for the development of p63-negative luminal cells [86–88]. Within the prostate epithelium,  $\Delta Np63$  is selectively expressed in the basal cell layer, while it is absent in the luminal and neuroendocrine cells [89]. In an in vitro study of prostate cell spheroid, p63-expressing cells are located in the outer layer of the spheres and exhibit self-renewal potential, while cells located in the center display a differentiated phenotype [30]. In addition, another in vitro prostasphere formation assay indicated that inhibiting p63 expression reduces prostate stem progenitor cells and promotes differentiation [90].

### Corneal epithelium

The self-renewing properties of the corneal epithelium are closely related to the integrity and function of the cornea [91, 92], which is closed to stem cells that reside in the basal epithelial layers of the limbal epithelium, called limbal epithelial stem cells (LESCs) [93]. The limbus is a narrow ring of tissue located between the cornea and conjunctive border, among which LESC give rise to progenitor cells that move toward the corneal center, through the suprabasal layers of the corneal epithelium (Fig. 3C). Under normal condition, the renewal of the corneal epithelium is carried out by LESC which express higher p63 levels than peripheral or central corneal epithelium cells [94]. The corneal epithelium of p63-null mice fails to maintain continuous development beyond ectodermal stage [95]. Heterozygous mutation in the TP63 gene is also responsible for LESC failure and results in drastic degeneration of corneal epithelial tissues [96].  $\Delta Np63\alpha$  is the predominantly expressed isoform in LESC and in limbal basal cells [97–99], but not in cells that cover the central corneal surface [96] (Fig. 3C). The expression of the  $\Delta Np63\alpha$  isoform allows LESC to produce TA cells, which are responsible for the generation and maintenance of the basal layer of the corneal epithelium [96]. Moreover,  $\Delta Np63\alpha$  is necessary for the maintenance of the proliferative [100] and migration potential of LESC during corneal wound healing [101].



In the absence of  $\Delta$ Np63, corneal epithelium renewal and terminal differentiation are impaired. However, an *in vitro* investigation demonstrated that TAp63 and  $\Delta$ Np63 expression appears to be specifically located in the limbus, while it and gradually decreases in the cornea, especially disappearing in the central cornea [102]. Furthermore, suppression of each of them affects the proliferation of limbal keratinocytes [102]. Besides, only TAp63 but not  $\Delta$ Np63 acts in a way that promotes cell differentiation [102].

### Thymus

Thymic epithelial precursor cells derive from the endoderm of the third pharyngeal pouch [103] and appear at E12 along with high levels of p63 expression [29]. p63 is required for maintaining the proliferative potential of stem cells in the thymus epithelium and is indispensable for thymus development and homeostasis. A study focusing on the impact of lineage-restricted p63 knockout (ko) in TECs on pre- and postnatal mice clearly defined that p63TECKo mice present severe thymic hypoplasia, which is characterized by a lack in well-defined segregation into medullary and cortical compartments [104]. Interestingly, the skin of p63TECKo mice shows continuous epidermis but no hair by 2 months of age [104]. Controversially, another study determined that thymus hypoplasia in p63-null embryo is attributed to decreased proliferative potential and increased apoptosis of TSCs, but p63 deficiency did not alter commitment and functional maturation of TSCs [29]. In an *in vitro* study, TSCs clones expressing p63 appear small and immature, while p63 shRNA expressing clones are large and present increased expression of the terminal differentiation markers after two-week culture [29], which means the symmetric expansion of TA cells [45]. In the developing of thymus, some abnormalities result from epithelial failure due to the absence of TSCs, which is attributed to the action of  $\Delta$ Np63 [32]. Correspondingly,  $\Delta$ Np63 isoform is the most abundant in both cortical and medullary TSCs [29, 105].

### Lung

Club cells are regional progenitor cells involved in the repair of the bronchiolar epithelium in response to lung damage. They give rise to epithelial alveolar type 2 cells (AT2s) and alveolar type 1 cells (AT1s) during the repair process. In addition, the distal airway stem/progenitor cells (DASCs) expressing p63 as well as keratin-5 (K5) are located in the airway basal epithelium and are responsible for lung regeneration after lung injury [106, 107]. In addition, induced p63<sup>+</sup>/KRT5<sup>+</sup> lung epithelial cells can give rise to alveoli, indicating the stemness potential [108, 109]. Upon mild-to-moderate pulmonary injury, surviving AT2s self-renew and differentiate into oxygen-exchanging AT1 population to carry out functionally beneficial tissue regeneration [110]. Abnormal epithelial remodeling follows severe lung injury, such as the one caused by pandemic H1N1 influenza and COVID-19, which has been shown to progressively induce the proliferation of p63-expressing epithelial cells [111]. Recently, a study focusing on acute lung injury (ALI) demonstrated that active p63 expression promotes proliferation and inhibits apoptosis in epithelial progenitor cells [112]. p63-positive cells arising from the lung primordium are primary multipotent progenitors of airway and alveolar lineages. These cells, located in intrapulmonary airway, maintain immature to adulthood in bronchi, where there is an important reservoir for establishing rare cell population that responds to H1N1 infection [108]. An *in vitro* investigation indicated that knockdown of p63 affects cellular morphology, proliferation, migration ability and results in impaired wound healing response and premature senescence in the airway epithelium [113]. In particular,  $\Delta$ Np63 is the principal isoform in human lung and exclusively enriched in the basal cells of the bronchial epithelium [113, 114]. Weiner and colleagues uncovered that  $\Delta$ Np63 restricts the plasticity of intrapulmonary DASCs by maintaining histone modifications at key gene loci [115].

Accordingly, DASCs undergo either airway or alveolar differentiation following loss of  $\Delta$ Np63. An age-associated decrease of TAp63 was observed in monkey. In contrast,  $\Delta$ Np63 expression showed a higher level, which triggers the migration of club cell (the second stem cell population in the airway epithelium) [116].

## SIGNALING INVOLVED IN P63-MEDIATED STEMNESS REGULATION

p63 regulates a wide range of target genes that are important for maintaining stemness in both physiological and pathological conditions. Some of them are discussed in the paragraphs below.

### The Notch pathway


A role for Notch signaling in stem cell preservation and cell fate determination has been described. Notch activation is able to promote self-renewal of stem cells, proliferation of progenitor cells, and commitment to specific cell lineages [117]. Notch proteins are cell-surface receptors (Notch1~4) that transduce signals upon interaction with transmembrane ligands such as Delta and Jagged (Jag), expressed on adjacent cells. They comprise an extracellular (NECD), a transmembrane (TM), and an intracellular (NICD) domain. In the canonical Notch signaling pathway, after three cleavages, the NICD directly translocates into the nucleus, where it mediates signaling through conversion of the DNA-binding protein from a repressor to an activator of transcription for the activation of target gene expression [118] (Fig. 4A, left panel).

Increased expression of Notch2 and Notch3 but decreased levels of Hes1 (Hairy and Enhancer of Split 1) and Notch1 were observed in the dorsal skin of mice lacking  $\Delta$ Np63 at E15.5, accompanied by diminished renewal capacity and an altered differentiation fate [73] (Fig. 4B, left panel). During thymic development, Jag2 displays high expression levels in the presence of  $\Delta$ Np63, by which Jag2 is involved in the maintenance of TECs' stemness [32]. In addition, in mouse keratinocytes,  $\Delta$ Np63a blocks Notch1-dependent growth arrest and differentiation by inhibiting p21 expression as well as maintaining integrin expression [119]. On the other hand, TAp63 $\beta/\gamma$  activates the transcription of late differentiation genes through the cooperation with Notch signaling. In particular, it upregulates HEY1 (Hes-related family bHLH transcription factor with YRPW motif 1) in human keratinocytes [120].

p63 and Notch also play antagonistic roles in controlling epithelial cell fates. In both mouse and human keratinocytes, p63 expression is inhibited by Notch1, while in contrast, upregulation of p63 oppositely regulates Notch target genes, mainly Hes1, and restricts the capability of Notch1 for inhibiting cell proliferation and promoting differentiation [51]. The Notch signaling pathway is activated during ectoderm specification, while its inactivation is necessary for promoting  $\Delta$ Np63 expression and epidermal keratinocyte lineage commitment [121]. As enriched  $\Delta$ Np63 expression indeed confers a basal phenotype in purified luminal cells, while Notch activation specifies a luminal cell fate [82]. Sierra Kent and colleagues demonstrated that  $\Delta$ Np63a inhibits cell-cycle progression and promotes cellular quiescence of mammary epithelial cells, predominantly through Notch3 regulation, thus providing novel mechanistic insights into the maintenance of mammary cellular quiescence by the p63/Notch axis [122]. In summary, the reciprocal antagonistic interactions of p63 isoforms and Notch family members determine the proper output of stemness regulation.

### The WNT/ $\beta$ -catenin pathway

WNT/ $\beta$ -catenin pathway is a highly conserved pathway involved in the maintenance of the progenitor cell population in the skin, limbus, intestine, mammary gland, and other epithelial tissues [123–126]. It's initiated by the interaction of the WNT ligands with



**Fig. 4 The signaling pathways involved in p63-mediated stemness regulation.** **A** The Notch (left), Wnt/ $\beta$ -catenin (middle), and Hh (right) pathway components modulated by p63 isoforms during ESCs' stemness regulation. All the encircled numbers indicate p63 isoform contribution by transcription regulation. **B** The reciprocal miRNA-p63 interactions are a vital factor in modulating p63 function, which is extensively involved in the development of the skin epidermis, including epithelial cell proliferation, differentiation, and senescence. **C** p63 regulates the stemness of ESCs through the signal molecules associated with epigenetic modifications. **D**  $\Delta$ Np63 controls the stemness of ESCs by regulating cell adhesion molecules. **E** Other signaling involved in p63-mediated modulation of ESCs' stemness. As shown,  $\Delta$ Np63 is the most studied isoform and it is involved in various cell mechanisms to achieve self-renewal and differentiation control of ESCs.

two cell-surface receptors Frizzled (Fzd) and an Lrp (Fig. 4A, middle panel). Then, induced Dishevelled (DVL) signaling cascade inhibits the  $\beta$ -catenin destruction complex in the cytoplasm, where  $\beta$ -catenin is constantly phosphorylated by the glycogen synthase kinase-3 $\beta$  (GSK-3 $\beta$ ) and, subsequently, rapidly ubiquitinated and targeted for proteasomal degradation. Finally, activated  $\beta$ -catenin translocates into the nucleus and regulates the expression of numerous target genes [127].

An investigation in normal mammary stem cell (MaSC) demonstrated that  $\Delta$ Np63 maintains their self-renewal ability through directly upregulating the expression of Fzd7 [31]. In turn, the WNT/ $\beta$ -catenin signaling could also be the upstream regulator of  $\Delta$ Np63, because of the presence of a putative  $\beta$ -catenin-RE within its promoter region. Limb-Bud and Heart (LBH), a transcription co-factor in the WNT pathway, upregulates the transcription of  $\Delta$ Np63 $\alpha$  but downregulates TAp63 $\alpha$  expression. By this way, LBH enhances the replicative potential as well as stemness of mammary basal ESCs and inhibits the transcription of luminal differentiation genes, such as ESR1/ER $\alpha$  (estrogen receptor  $\alpha$ ) [81].

**The Hedgehog signaling pathway**

The Hedgehog (Hh) signaling is triggered by the binding of one of the three secreted ligands, Sonic Hedgehog (Shh), Indian Hedgehog (Ihh) or Desert Hedgehog (Dhh) to the Patched1 (PTCH1) receptor. Upon binding, PTCH1 releases its inhibition on Smoothened (SMO), that then transduces the Hh signal across the cell membrane, activating the Glioma-associated oncogene homologs family (GLI1, GLI2, and GLI3) of transcription factors [128].

The Hh signaling pathway is a crucial driver of ESC self-renewal [129]. Reciprocal interactions between p63 and the Hh signaling components regulate quiescence and activation of ESCs (Fig. 4A, right panel). p63 contributes to the stemness phenotype through its ability to bind to the promoters of Hh components, assigning positive and negative regulation to Ihh by TAp63 and  $\Delta$ Np63 isoforms, respectively [75]. Conversely, Ihh-induced GLI3 upregulates TAp63 expression but reduces the usage of the  $\Delta$ Np63 promoter, through which the Hh signaling plays an important role in the elaboration and differentiation of mammary progenitors and decreased clonogenicity of MaSCs in vitro [75]. During keratinocyte differentiation, an active Hh signaling pathway is observed in proliferating cells, in which it triggers the expression of  $\Delta$ Np63 $\alpha$  and further activates SUFU transcription. In turn, increased SUFU inhibits GLI-targeted genes, including  $\Delta$ Np63 $\alpha$ , and then restrains proliferation and promotes differentiation of keratinocytes [130]. On the other hand, constitutively activated Hh signaling in palatal epithelium results in the persistence of p63 signaling and p63-targeted genes in medial edge epithelium, which directly enhancing the epithelial progenitor cell-associated genes [131]. In epididymal, ARL13B is responsible for epithelium integrity and tissue regeneration. In its absence, the Hh signaling is impaired and basal cell markers, such as p63 are lost [132].

**Noncoding RNAs**

The reciprocal microRNA (miRNA)-p63 interaction is a vital factor that modulates p63 function [133], and miRNA plays a crucial role

in the modulation of stem cell senescence and proliferation [134–137] (Fig. 4B). miR-203 is a key molecule controlling the proliferative potential and inducing cell-cycle arrest of epithelial precursor cells during epithelial development. Mechanistically, it inhibits p63 activity through targeting human and mouse p63 3'-UTR, especially  $\Delta$ Np63 [44, 55, 138]. Consistently, increased expression of miR-203 by oleic acid (OA), an unsaturated free fatty acid (FFA), enhances the differentiation of keratinocytes through reducing p63 expression [139]. Besides, the proliferation of human primary keratinocytes *in vitro* coincides with the increased miR-130b, whose overexpression will induce cell senescence through inhibition of  $\Delta$ Np63 expression. However,  $\Delta$ Np63 $\alpha$ , in turn, inhibits miR-130b expression in primary keratinocytes, thus promoting their growth [140].  $\Delta$ Np63 $\alpha$ -inhibited miR-138, miR-181a, miR-181b, and miR-130b participate in the growth-promoting of epidermal proliferating cells and keratinocyte senescence [140]. Furthermore, miR-574-3p and miR-720 function as regulator of keratinocyte differentiation by linking iASPP, an inhibitory member of ASPP (apoptosis stimulating protein of p53) family, and silencing of iASPP in keratinocytes accelerates the differentiation pathway through indirectly increasing protein level of  $\Delta$ Np63 [141].

Several long noncoding RNAs (lncRNAs) have been implicated in keratinocyte biology, through either the maintenance of the undifferentiated state of the progenitor cells or the induction of epidermal differentiation [142–144]. In addition, lncRNAs are crucially involved in the development and progression of several human epithelial cancers [142, 145–149]. There is emerging evidence that some of the lncRNAs regulating epidermal differentiation are functionally related to p63. For instance, beta1-adjacent-lncRNA (BLNCR) is a p63-regulated lncRNA, whose expression has been associated with the proliferative potential of epidermal stem cells since it undergoes rapid downregulation upon differentiation induction [150]. Fierro and colleagues identified a significant number of annotated lncRNAs, whose expression was differentially regulated in epidermal keratinocytes upon  $\Delta$ Np63 inactivation [151]. Among the most modulated lncRNAs in p63-depleted cells, they found downregulation of MIR17HG and BCRNY, and upregulation of FTX, MALAT1, and NEAT1. In proliferating keratinocytes,  $\Delta$ Np63 negatively regulates the expression of MALAT1 and NEAT1 by recruiting the histone deacetylase HDAC1 to their promoter regions. HDAC1 then reduces histone H3 acetylation on the promoter regions of NEAT1 and MALAT1, ultimately leading to their transcriptional repression. Upon induction of differentiation,  $\Delta$ Np63 downregulation results in enhanced levels of NEAT1, which then controls the expression of epidermal genes to promote keratinocyte differentiation.

### Epigenetic modifiers


ESCs' stemness properties are also under the control of epigenetic modifications (Fig. 4C). p63 binds to the regulatory region of *Satb1* gene, a genome organizer, contributing to epidermal morphogenesis through tissue-specific chromatin organization [152]. As demonstrated, the expression *Satb1* in p63 (+/–) mice skin explants partially restores the epidermal phenotype. The endogenous DNA methyltransferase 3A (DNMT3a) cooperates with p63 to maintain a high level of DNA hydromethylation at enhancer sites in a Tet2-dependent manner, thus preserving the self-renewal potential of human epidermal stem cells (EpSCs) [153]. Cbx4, a component of Polycomb Repressive Complex 1 (PRC1) highly expressed in thymus epithelium, physically interacts with p63 and thereby contributes to the maintenance of stemness in epithelial progenitors [154]. Similarly, Cbx4 is decreased in p63 knockout keratinocytes, and Cbx4 knockout mice exhibit impaired cell proliferation and premature terminal differentiation during epidermis development [155].

### Cell adhesion molecules

Interestingly, p63 has also been reported to participate in the regulation of anoikis by modulating cell adhesion [156], which is essential for progenitor cell maintenance. The interaction between integrins and receptors for growth factors and cytokines creates a complex web of signaling pathways that impact ESCs niche. As depicted in Fig. 4D, deficiency of p63 results in the downregulation of genes associated with cell adhesion, such as ITGB4, which encodes  $\beta$ 4 integrin (also known as CD29).  $\Delta$ Np63 $\alpha$  specifically upregulates  $\beta$ 4 integrin, leading to cell detachment and anoikis in mammary epithelial cells and keratinocytes. Consistently,  $\beta$ 4 integrin partially protects against p63 loss-induced anoikis [156]. Furthermore, the knockdown of p63 (TAp63 $\gamma$  and  $\Delta$ Np63 $\alpha$ ) impairs the expression of cell adhesion molecules, such as human ITGA3, which encodes the integrin subunit  $\alpha$ 3 that combines with integrin  $\beta$ 1 to form the  $\alpha$ 3 $\beta$ 1 dimer, by which p63 is thought to facilitate the anchoring of ESCs to their niche [156, 157].

### Other signaling

There are many other signaling molecules that are also involved in p63-mediated regulation of epithelial stem cell stemness (Fig. 4E). Metabolic regulation [158, 159], and reactive oxygen species (ROS) [160] are essential in all biological functions. The epidermis is subjected to significant oxidative stress due to the production of ROS during aerobic metabolism [161, 162]. REDD1 (regulated in development and DNA damage responses 1), a regulator in DNA damage response (DRR), appears to function as a regulator of cellular ROS. p63 expression, especially TAp63 $\gamma$  and  $\Delta$ Np63 $\alpha$ , coincides with that of REDD1 in undifferentiated human primary keratinocytes. The downregulation of anyone of this two isoforms dramatically restricts REDD1 expression and promotes the differentiation program through increased ROS levels, suggesting that the p63-REDD1-ROS axis is responsible for preserving the undifferentiated state [163]. p63 isoforms are also known as vital regulators of energy metabolism. Hamanaka and Mutlu proposed that p63 affects cellular glycolytic rate of keratinocytes by regulating the transcriptional expression of metabolic enzyme phosphofructokinase-2/fructose-2,6-bisphosphatase 3 (PFKFB3), thereby resulting in a proliferation/differentiation switch [164, 165]. Smirnov and colleagues demonstrated that Zinc finger protein 185 (ZNF185) contributes to maintain epithelial integrity and epithelial differentiation potential through the specific binding of p63 to its enhancer region in keratinocytes [166]. In the mouse epidermis, the activation of protein kinase p38 $\alpha$  phosphorylates and destabilizes  $\Delta$ Np63 $\alpha$ . Conversely, p38 $\alpha$  deficiency stabilizes  $\Delta$ Np63 $\alpha$  and promote keratinocyte colony formation [167]. Steap4 (Six-Transmembrane Epithelial Antigen of Prostate 4)- $\Delta$ Np63 axis induced by interleukin-17 (IL-17) is positively related to the TRAF4 (TNF Receptor-Associated Factor 4)-ERK5 axis through p63-mediated TRAF4 expression, by which IL-17 favors keratinocyte proliferation [168]. Gatti et al. found that Senataxin (SETX), an RNA/DNA helicase, acts as a key molecule of skin homeostasis by regulating a series of genes involved in the early step of keratinocyte differentiation program together with  $\Delta$ Np63 [169]. Additionally, the RING finger E3 ubiquitin ligase PIR2 (also known as Rnf144b) has been identified as a target of  $\Delta$ Np63 $\alpha$ , which in turn induces the degradation of  $\Delta$ Np63 $\alpha$ , impairing keratinocyte proliferation and differentiation [170]. In the mammary epithelium,  $\Delta$ Np63 activates canonical bone morphogenic proteins (BMPs) signaling by inducing the transcription of BMP7, which then fosters the stem cell phenotype of mammary progenitors [171]. I $\kappa$ B kinase (IKK), one of the three main subunits of NF- $\kappa$ B complex, consists of two catalytic subunits, IKK $\alpha$  and IKK $\beta$ , as well as a regulatory subunit, IKK $\gamma$ . TAp63 acts as the upstream regulator of IKK $\alpha$  through direct transactivation and also indirectly through Ets-1 (E26 transformation-specific-1). In contrast,  $\Delta$ Np63 only indirectly



**Fig. 5** The signaling pathway by which p63 affects CSCs in epithelial cancers. **A** Distinct expression levels of the p63 protein in different tumor tissues (The Human Protein Atlas, <https://www.proteinatlas.org/ENSG00000073282-TP63/pathology>). **B** The  $\Delta$ Np63 isoform plays a crucial role in regulating various signaling pathways implicated in CSC stemness regulation, particularly in breast and SCC cancers. **C** p63 regulates ALDH1A1 in the context of prostate cancer, in which p63 affects CSC stemness. **D** TAp63 modulates the expression of specific Hippo pathway components to regulate the stemness of CSCs in breast cancer.

activates IKK $\alpha$  through GATA3 in keratinocytes during epithelial development [172].

### P63 AND CANCER STEM CELL IN EPITHELIAL TUMOR

TP63 is rarely mutated in human cancers but its expression and activity are often increased [173–175] (Fig. 5A). The human TP63 gene exhibits increased expression in 88% squamous carcinomas and 42% of large cell carcinomas and lung adenocarcinomas [176]. Among p63 isoforms,  $\Delta$ Np63 is the predominant expressed isoform in various epithelial tumors and its alterations positively correlate with increased metastatic potential and therapy resistance [174, 177, 178]. Emerging evidence suggests that several tumors are maintained by tumor-initiating cells (TICs), also referred as cancer stem cells (CSCs), possessing stem-like properties [179, 180]. CSCs are considered as the cellular “seeds” of tumor recurrence, metastasis and therapy resistance [181–184]. Like in normal tissues, self-renewal and differentiation of rare CSCs are essential and responsible for the growth of the tumor mass [185, 186]. Growing evidence suggests that abnormal signaling within pathways that regulate the stemness properties of normal stem cells may contribute to foster survival of CSCs. Most importantly, increasing evidence is pointing at the regulation of CSCs by p63 in various epithelial cancers [87, 174].

$\Delta$ Np63 is enriched in breast cancer CSCs and promotes their colony formation ability [31] (Fig. 5B). Memmi and colleagues reported that  $\Delta$ Np63 is preferentially expressed in CSCs from transgenic mice with mammary gland targeted ErbB2 (MMTV-Erb2) tumors and is required to maintain their self-renewal potential. Mechanistically,  $\Delta$ Np63 directly binds to the gene regulatory regions of Shh, Gli2, and Ptch1 genes, regulating their expression and ultimately contributing to pathway activation [187]. Additionally, p63 inactivation in ErbB2 progenitors reduces the transcription of genes for encoding components of the Shh

signaling, to which mainly  $\Delta$ Np63 isoform contributes, thus attenuating mammary CSC self-renewal [187]. Similar to the normal counterparts, the tumor-initiating activity of CSCs of basal breast cancer is governed by  $\Delta$ Np63-dependent transcription of Fzd7 [31]. A clinical study showed that  $\Delta$ Np63 was enriched in a cell subpopulation from triple negative breast cancer patients. Furthermore,  $\Delta$ Np63 $\alpha$  positively correlates with Notch1 expression by directly binding to its promoter, and increases the fraction of CSC-like cells in a luminal breast cancer cell line [188]. The interaction between  $\Delta$ Np63 and BMPs, especially BMP7, is able to commit human breast cancer cells to a stem-like phenotype [171]. The  $\Delta$ Np63 isoform stimulates the transcription of the gene that encodes the cell-surface antigen CD44, a marker associated with cancer stem cells in breast, colorectal, and squamous cell carcinomas [189, 190]. Albeit at levels lower than in normal prostate, p63 expression is essential for regulating stem cell functions of neoplastic prostate epithelial cells. Cytoplasmic aberrance of p63 is associated with high ALDH1A1 (Aldehyde Dehydrogenase 1 Family, Member A1) expression, thus leading to increased cell proliferation rate of prostate CSCs [191] (Fig. 5C). Su and colleagues demonstrated that TAp63 is the main regulator of the transition from mammary cells to TICs (Fig. 5D). In the absence of TAp63, mammary epithelial cells (MECs) unleash stemness potential by expressing MaSCs signatures as well as by activating the Hippo pathway. Therefore, TAp63 null mice develop aggressive metastasis [192].

In the skin,  $\Delta$ Np63 $\alpha$  acts as an oncogene, capable of inhibiting oncogene-induced senescence and promoting development of squamous cell carcinoma (SCC) (Fig. 5B).  $\Delta$ Np63 $\alpha$  cooperates with oncogenic RAS to promote proliferation and to maintain the KRT15-positive stem cell population in order to drive tumorigenesis in vivo [193]. The expression of Lsh, a chromatin-remodeling protein is regulated by  $\Delta$ Np63 $\alpha$  during senescence bypass and tumor initiation, suggesting that p63 plays a role in epigenetic



regulation of stemness [193]. Enhancer zest homolog 2 (EZH2) and SET domain bifurcated 1 (SETDB1) are two well-known oncogenic methyltransferases that are highly expressed in stem-like SSC sub-populations. SETDB1 cooperates with  $\Delta$ Np63 $\alpha$  to regulate the SCC stem cell phenotype. In addition, EZH2-activated RUNX3 acts as an inhibitor of both SETD1 and  $\Delta$ Np63 $\alpha$  [194].  $\Delta$ Np63 is often overexpressed in SCCs, in which it acts as a master regulator of CSCs maintenance via its functional connection with signal transducer and activator of transcription 3 (STAT3), assigning STAT3 induces  $\Delta$ Np63 expression through binding to its promoter [195–197]. The gene encoding the chromatin-modifying protein that ACTL6A (Actin-like protein 6A) is coamplified with *p63* locus in HNSCC and induces a CSC phenotype characterized by undifferentiated regenerative proliferation. They also found ACTL6A/*p63* complex is a direct transcription suppressor of Hippo regulator WWC1 and thus promotes YAP-mediated tumorigenesis [198]. Additionally, transglutaminase 2 (TG2) is an effector required for CSC survival in epidermal SCC. The interaction between TG2 and  $\alpha$ 6/ $\beta$ 4-integrin is able to induce YAP-dependent  $\Delta$ Np63 $\alpha$  stabilization and therefore leads to enhanced tumor stem cell properties [199]. The Ribosomal S6 protein kinase 4 (RSK4) is one of the direct downstream targets of  $\Delta$ Np63 $\alpha$  in CSC maintaining in esophageal squamous cell carcinoma. As found,  $\Delta$ Np63 $\alpha$  directly transactivates RSK4 expression, thereby inhibiting radiosensitivity through GSK-3 $\beta$ /catenin axis [200]. Additionally,  $\Delta$ Np63 regulates the self-renewal and maintenance of LESC, which are indispensable for lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC) initiation as well as progression through the regulation of a common landscape of enhancer-associated cell identity genes, such as BCL9L (B-cell CLL/lymphoma 9-like) [201].

Altered expression of *p63* in tumors correlates with aberrant expression of *p53* or with the presence of *TP53* mutants, indicating that the *p63*-*p53* axis is relevant to tumorigenesis. Several *p53* mutant proteins can interact with *p63* through the OD, resulting in the inhibition of the transcriptional activity of the TAp63 variants and, subsequently, of their tumor suppressive behavior [2, 202]. Other *p53* mutations occurring in the DBD render this domain very unstable, thus resulting in *p63* $\alpha$  binding via a co-aggregation mechanism mediated by the TIDs of the  $\alpha$ -isoforms [203]. Inactivation of *p63* by *p53* mutants has been associated with the ability of mutant *p53* proteins to promote tumor growth, chemoresistance, and metastasis [204]. Mechanistically, during tumor progression, tumor growth factor- $\beta$  (TGF- $\beta$ ), acting in concert with oncogenic RAS, induces the formation of a mutant-*p53*/*p63*/SMADs ternary protein complex, in which the SMADs are essential platforms for the complex to assembly [202]. As a result of this interplay, the anti-metastatic properties of TAp63 are inhibited, allowing cancer cells to acquire pro-invasive and migratory capabilities. Mutant *p53* proteins was also found to recruit *p63* to gene promoters. In this context, *p63* serves as a molecular chaperone through which *p53* mutants aberrantly reprogram the cancer cell transcriptome and facilitate tumor invasion [205]. Zhang and colleagues reported that mutant *p53* is capable of antagonizing *p63*-mediated tumor suppression in an in vivo model of T lymphoblastic lymphomas (T-ALL) [206]. In particular, mutant *p53* contributes to the pathogenesis of T-ALL by collaborating with NOTCH1 to hijack *p63*-mediated transcription. Other studies have highlighted the ability of some *p53* mutants to potentiate  $\Delta$ Np63 function via protein-protein interaction [207].

Growing evidence has implicated *p63* as a critical factor in driving the metastatic cascade (Fig. 5B).  $\Delta$ Np63 acts as a vital regulator of quasi-mesenchymal CSCs which drive the metastatic events, and is required for the post-extravasation proliferation of CSCs in human breast cancer [208]. In the early stage,  $\Delta$ Np63 $\alpha$  is responsible for local invasion through collaborating with the membrane-type 1 (MT1)-matrix metalloproteinase (MMP) in basal-

like BC, assigning to  $\Delta$ Np63 $\alpha$  the role in inhibiting the transcription of MT1-MMP [209]. One of the main traits of CSCs is the epithelial-mesenchymal transition process. Activation of oncogenic RAS or the TGF- $\beta$  signaling in breast cancer cells stimulates  $\Delta$ Np63 transcriptional activity and then induces the transcription of the dual-specificity phosphatase 6 (DUSP6) gene, whose expression is mainly restricted to stem cells [210]. As a result, DUSP6 empowers  $\Delta$ Np63 and promotes metastatic behaviors in breast cancer cells [211]. In prostate adenocarcinomas,  $\Delta$ Np63 is associated with the onset of basal-like cancer stem cell population but not with metastasis, as none of the tumors expressing *p63* showed bone metastasis [212].

## CONCLUSIONS

*p63* is a *p53* family protein responsible for morphogenesis and postnatal regeneration of epithelial tissues [213]. TAp63 and  $\Delta$ Np63 isoforms, expressed in a variety of epithelial tissues and in epithelium-derived tumors, affect the transcriptions of genes involved in different mechanisms of stemness regulation. In this review, we outline the contribution of TAp63 and  $\Delta$ Np63 isoforms to stemness in epithelial tissues. We also report about their involvement in the regulation of multiple signaling pathways, in both physiological and pathological conditions. In general, by sharing the ability of *p53* to induce cell-cycle arrest and apoptosis, TAp63 often acts as a tumor suppressor [23, 214]. In contrast,  $\Delta$ Np63 mainly works as an oncogene through orchestrating several tumor-promoting pathways, thus being suggested as a marker of CSCs [215, 216]. Therefore, the balance between TAp63 and  $\Delta$ Np63 appears to modulate cell fate decisions. In either normal ESCs or CSCs, our work clearly shows that *p63* participates in multiple pathways related to the regulation of self-renewal and functional differentiation. Collectively, *p63* isoforms play an indispensable role in regulating normal ESCs and CSCs stemness for epithelium regeneration and tumorigenesis, respectively. Further investigations on *p63* upstream signaling and affected targets would allow to acquire thorough insights into the network centered on this pivotal transcription factor, finally contributing to the achievement of a deeper knowledge of stemness mechanisms, aimed at the development of new therapeutic strategies.

## REFERENCES

- De Laurenzi V, Melino G. Evolution of functions within the *p53/p63/p73* family. *Ann N Y Acad Sci*. 2000;926:90–100.
- Candi E, Agostini M, Melino G, Bernassola F. How the TP53 family proteins TP63 and TP73 contribute to tumorigenesis: regulators and effectors. *Hum Mutat*. 2014;35:702–14.
- Bernassola F, Salomoni P, Oberst A, Di Como CJ, Pagano M, Melino G, et al. Ubiquitin-dependent degradation of *p73* is inhibited by PML. *J Exp Med*. 2004;199:1545–57.
- Pignon JC, Grisanzio C, Geng Y, Song J, Shivdasani RA, Signoretti S. *p63*-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia. *Proc Natl Acad Sci USA* 2013;110:8105–10.
- Vitale I, Pietrocola F, Guilbaud E, Aaronson SA, Abrams JM, Adam D, et al. Apoptotic cell death in disease—Current understanding of the NCCD 2023. *Cell Death Differ*. 2023;30:1097–154.
- Priami C, Montariello D, De Michele G, Ruscitto F, Polazzi A, Ronzoni S, et al. Aberrant activation of *p53/p63*Shc-Mlnsc axis increases asymmetric divisions and attenuates proliferation of aged mammary stem cells. *Cell Death Differ*. 2022;29:2429–44.
- Thomas AF, Kelly GL, Strasser A. Of the many cellular responses activated by TP53, which ones are critical for tumour suppression? *Cell Death Differ*. 2022;29:961–71.
- Kennedy MC, Lowe SW. Mutant *p53*: it's not all one and the same. *Cell Death Differ*. 2022;29:983–7.
- Hoyos D, Greenbaum B, Levine AJ. The genotypes and phenotypes of missense mutations in the proline domain of the *p53* protein. *Cell Death Differ*. 2022;29:938–45.

10. de Andrade KC, Lee EE, Tookmanian EM, Kesserwan CA, Manfredi JJ, Hatton JN, et al. The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute. *Cell Death Differ.* 2022;29:1071–3.
11. Levine AJ. Exploring the future of research in the Tp53 field. *Cell Death Differ.* 2022;29:893–4.
12. El-Saafin F, Bergamasco MI, Chen Y, May RE, Esakky P, Hediye-Zadeh S, et al. Loss of TAF8 causes TFIID dysfunction and p53-mediated apoptotic neuronal cell death. *Cell Death Differ.* 2022;29:1013–27.
13. Lindstrom MS, Bartek J, Maya-Mendoza A. p53 at the crossroad of DNA replication and ribosome biogenesis stress pathways. *Cell Death Differ.* 2022;29:972–82.
14. Engeland K. Cell cycle regulation: p53-p21-RB signaling. *Cell Death Differ.* 2022;29:946–60.
15. Murray-Zmijewski F, Lane DP, Bourdon JC. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. *Cell Death Differ.* 2006;13:962–72.
16. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. *Mol Cell.* 1998;2:305–16.
17. Mangiulli M, Valletti A, Caratozzolo MF, Tullo A, Sbsia E, Pesole G, et al. Identification and functional characterization of two new transcriptional variants of the human p63 gene. *Nucleic Acids Res.* 2009;37:6092–104.
18. de Biase D, Morandi L, Degli Esposti R, Ligorio C, Pession A, Foschini MP, et al. p63 short isoforms are found in invasive carcinomas only and not in benign breast conditions. *Virchows Arch.* 2010;456:395–401.
19. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. *Nature.* 1999;398:708–13.
20. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. *Nature.* 1999;398:714–8.
21. Koster MI, Dai D, Marinari B, Sano Y, Costanzo A, Karin M, et al. p63 induces key target genes required for epidermal morphogenesis. *Proc Natl Acad Sci USA.* 2007;104:3255–60.
22. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. *Nature.* 2002;416:560–4.
23. Guo X, Keyes WM, Papazoglu C, Zuber J, Li W, Lowe SW, et al. TAp63 induces senescence and suppresses tumorigenesis in vivo. *Nat Cell Biol.* 2009;11:1451–7.
24. Suh EK, Yang A, Kettenbach A, Bamberger C, Michaelis AH, Zhu Z, et al. p63 protects the female germ line during meiotic arrest. *Nature.* 2006;444:624–8.
25. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D, et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. *Cancer Cell.* 2005;7:363–73.
26. Candi E, Melino G, Toth A, Dotsch V. Mechanisms of quality control differ in male and female germ cells. *Cell Death Differ.* 2021;28:2300–2.
27. Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, Hill DE, et al. AIS is an oncogene amplified in squamous cell carcinoma. *Proc Natl Acad Sci USA.* 2000;97:5462–7.
28. Moore JE, McMullen CB, Mahon G, Adamis AP. The corneal epithelial stem cell. *DNA Cell Biol.* 2002;21:443–51.
29. Senoo M, Pinto F, Crum CP, McKeon F. p63 is essential for the proliferative potential of stem cells in stratified epithelia. *Cell.* 2007;129:523–36.
30. Xin L, Lukacs RU, Lawson DA, Cheng D, Witte ON. Self-renewal and multilineage differentiation in vitro from murine prostate stem cells. *Stem Cells.* 2007;25:2760–9.
31. Chakrabarti R, Wei Y, Hwang J, Hang X, Andres Blanco M, Choudhury A, et al. DeltaNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. *Nat Cell Biol.* 2014;16:1004–15.
32. Candi E, Rufini A, Terrinoni A, Giamboi-Miraglia A, Lena AM, Mantovani R, et al. DeltaNp63 regulates thymic development through enhanced expression of Fgfr2 and Jag2. *Proc Natl Acad Sci USA.* 2007;104:11999–2004.
33. Su X, Chakravarti D, Flores ER. p63 steps into the limelight: crucial roles in the suppression of tumorigenesis and metastasis. *Nat Rev Cancer.* 2013;13:136–43.
34. Pecorari R, Bernassola F, Melino G, Candi E. Distinct interactors define the p63 transcriptional signature in epithelial development or cancer. *Biochem J.* 2022;479:1375–92.
35. King KE, Weinberg WC. p63: defining roles in morphogenesis, homeostasis, and neoplasia of the epidermis. *Mol Carcinog.* 2007;46:716–24.
36. Koster MI, Roop DR. Transgenic mouse models provide new insights into the role of p63 in epidermal development. *Cell Cycle.* 2004;3:411–3.
37. Tai K, Cockburn K, Greco V. Flexibility sustains epithelial tissue homeostasis. *Curr Opin Cell Biol.* 2019;60:84–91.
38. Blanpain C, Fuchs E. Stem cell plasticity. Plasticity of epithelial stem cells in tissue regeneration. *Science.* 2014;344:1242281.
39. Harris-Tryon TA, Grice EA. Microbiota and maintenance of skin barrier function. *Science.* 2022;376:940–5.
40. Yuan X, Chen J, Grauer JA, Xu Q, Van Brunt LA, Helms JA. The junctional epithelium is maintained by a stem cell population. *J Dent Res.* 2021;100:209–16.
41. Forster N, Saladi SV, van Bragt M, Sfoudouris ME, Jones FE, Li Z, et al. Basal cell signaling by p63 controls luminal progenitor function and lactation via NRG1. *Dev Cell.* 2014;28:147–60.
42. McKeon F. p63 and the epithelial stem cell: more than status quo? *Genes Dev.* 2004;18:465–9.
43. Ratajczak MZ, Bujko K, Mack A, Kucia M, Ratajczak J. Cancer from the perspective of stem cells and misappropriated tissue regeneration mechanisms. *Leukemia.* 2018;32:2519–26.
44. Yi R, Poy MN, Stoffel M, Fuchs E. A skin microRNA promotes differentiation by repressing 'stemness'. *Nature.* 2008;452:225–9.
45. Melino G, Memmi EM, Pelicci PG, Bernassola F. Maintaining epithelial stemness with p63. *Sci Signal.* 2015;8:re9.
46. Koster MI, Huntzinger KA, Roop DR. Epidermal differentiation: transgenic/knockout mouse models reveal genes involved in stem cell fate decisions and commitment to differentiation. *J Investig Dermatol Symp Proc.* 2002;7:41–45.
47. Su X, Cho MS, Gi YJ, Ayanga BA, Sherr CJ, Flores ER. Rescue of key features of the p63-null epithelial phenotype by inactivation of Ink4a and Arf. *EMBO J.* 2009;28:1904–15.
48. Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR. p63 is the molecular switch for initiation of an epithelial stratification program. *Genes Dev.* 2004;18:126–31.
49. Pellegrini G, Dellambra E, Golisano O, Martinelli E, Fantozzi I, Bondanza S, et al. p63 identifies keratinocyte stem cells. *Proc Natl Acad Sci USA.* 2001;98:3156–61.
50. Kai-Hong J, Jun X, Kai-Meng H, Ying W, Hou-Qi L. P63 expression pattern during rat epidermis morphogenesis and the role of p63 as a marker for epidermal stem cells. *J Cutan Pathol.* 2007;34:154–9.
51. Nguyen BC, Lefort K, Mandinova A, Antonini D, Devgan V, Della Gatta G, et al. Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. *Genes Dev.* 2006;20:1028–42.
52. Koster MI, Roop DR. The role of p63 in development and differentiation of the epidermis. *J Dermatol Sci.* 2004;34:3–9.
53. Crum CP, McKeon FD. p63 in epithelial survival, germ cell surveillance, and neoplasia. *Annu Rev Pathol.* 2010;5:349–71.
54. Voroteliak EA, Chermnykh ES, Tkachenko SB, Vasil'ev AV, Tersikh VV. [Expression and function of p63 gene in epithelial cells]. *Izv Akad Nauk Ser Biol.* 2007;4:389–93.
55. Lena AM, Shalom-Feuerstein R, Rivetti di Val Cervo P, Aberdam D, Knight RA, Melino G, et al. miR-203 represses 'stemness' by repressing DeltaNp63. *Cell Death Differ.* 2008;15:1187–95.
56. Koster MI, Kim S, Roop DR. P63 deficiency: a failure of lineage commitment or stem cell maintenance? *J Investig Dermatol Symp Proc.* 2005;10:118–23.
57. Su X, Paris M, Gi YJ, Tsai KY, Cho MS, Lin YL, et al. TAp63 prevents premature aging by promoting adult stem cell maintenance. *Cell Stem Cell.* 2009;5:64–75.
58. Beaudry VG, Attardi LD. SKP-1ng TAp63: stem cell depletion, senescence, and premature aging. *Cell Stem Cell.* 2009;5:1–2.
59. Mikkola ML. p63 in skin appendage development. *Cell Cycle.* 2007;6:285–90.
60. Koster MI, Roop DR. p63 and epithelial appendage development. *Differentiation.* 2004;72:364–70.
61. Sun X, Joost S, Kasper M. Plasticity of epithelial cells during skin wound healing. *Cold Spring Harb Perspect Biol.* 2023;15:a041232.
62. Gebel J, Luh LM, Coutandin D, Osterburg C, Lohr F, Schafer B, et al. Mechanism of TAp73 inhibition by DeltaNp63 and structural basis of p63/p73 heterotetramerization. *Cell Death Differ.* 2016;23:1930–40.
63. Liu F, Zhou H, Du W, Huang X, Zheng X, Zhang C, et al. Hair follicle stem cells combined with human allogeneic acellular amniotic membrane for repair of full thickness skin defects in nude mice. *J Tissue Eng Regen Med.* 2020;14:723–35.
64. Drewa T, Joachimiak R, Kaznica A, Sarafian V, Pokrywczynska M. Hair stem cells for bladder regeneration in rats: preliminary results. *Transpl Proc.* 2009;41:4345–51.
65. Shin JW, Choi HR, Nam KM, Lee HS, Kim SA, Joe HJ, et al. The co-expression pattern of p63 and HDAC1: a potential way to disclose stem cells in interfollicular epidermis. *Int J Mol Sci.* 2017;18:1360.
66. Fiuraskova M, Brychtova S, Kolar Z, Kucerova R, Bienova M. Expression of beta-catenin, p63 and CD34 in hair follicles during the course of androgenetic alopecia. *Arch Dermatol Res.* 2005;297:143–6.
67. Van Tri M, Polonsky J, Merienne C, Sevenet T. Soularubinone, a new antileukemic quassonoid from *Soulaea tomentosa*. *J Nat Prod.* 1981;44:279–84.
68. Nelson AM, Katseff AS, Ratliff TS, Garza LA. Interleukin 6 and STAT3 regulate p63 isoform expression in keratinocytes during regeneration. *Exp Dermatol.* 2016;25:155–7.

69. Romano RA, Smalley K, Liu S, Sinha S. Abnormal hair follicle development and altered cell fate of follicular keratinocytes in transgenic mice expressing DeltaNp63alpha. *Development*. 2010;137:1431–9.
70. Yang X, Wang H, Jiao B. Mammary gland stem cells and their application in breast cancer. *Oncotarget*. 2017;8:10675–91.
71. Wuidart A, Sifrim A, Fioramonti M, Matsumura S, Brisebarre A, Brown D, et al. Early lineage segregation of multipotent embryonic mammary gland progenitors. *Nat Cell Biol*. 2018;20:666–76.
72. van Bokhoven H, Jung M, Smits AP, van Beersum S, Ruschendorf F, van Steensel M, et al. Limb mammary syndrome: a new genetic disorder with mammary hypoplasia, ectrodactyly, and other Hand/Foot anomalies maps to human chromosome 3q27. *Am J Hum Genet*. 1999;64:538–46.
73. Romano RA, Smalley K, Magraw C, Serna VA, Kurita T, Raghavan S, et al. DeltaNp63 knockout mice reveal its indispensable role as a master regulator of epithelial development and differentiation. *Development*. 2012;139:772–82.
74. Coates PJ, Nenutil R, Holcakova J, Nekulova M, Podhorec J, Svoboda M, et al. p63 isoforms in triple-negative breast cancer: DeltaNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival. *Virchows Arch*. 2018;472:351–9.
75. Li N, Singh S, Cherukuri P, Li H, Yuan Z, Ellis LW, et al. Reciprocal intraepithelial interactions between TP63 and hedgehog signaling regulate quiescence and activation of progenitor elaboration by mammary stem cells. *Stem Cells*. 2008;26:1253–64.
76. Yallowitz AR, Alexandrova EM, Talos F, Xu S, Marchenko ND, Moll UM. p63 is a prosurvival factor in the adult mammary gland during post-lactational involution, affecting PI-MECs and ErbB2 tumorigenesis. *Cell Death Differ*. 2014;21:645–54.
77. Barbareschi M, Pecciarini L, Cangini MG, Macri E, Rizzo A, Viale G, et al. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. *Am J Surg Pathol*. 2001;25:1054–60.
78. Nylander K, Vojtesek B, Nenutil R, Lindgren B, Roos G, Zhanxiang W, et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. *J Pathol*. 2002;198:417–27.
79. Kudo KI, Tsuyama N, Nagata K, Imaoka T, Iizuka D, Sugai-Takahashi M, et al. DeltaNp63alpha transcriptionally represses p53 target genes involved in the radiation-induced DNA damage response: DeltaNp63alpha may cause genomic instability in epithelial stem cells. *Radiat Oncol*. 2022;17:183.
80. DiRenzo J, Signoretti S, Nakamura N, Rivera-Gonzalez R, Sellers W, Loda M, et al. Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. *Cancer Res*. 2002;62:89–98.
81. Lindley LE, Curtis KM, Sanchez-Mejias A, Rieger ME, Robbins DJ, Briegel KJ. The WNT-controlled transcriptional regulator LBH is required for mammary stem cell expansion and maintenance of the basal lineage. *Development*. 2015;142:893–904.
82. Yalcin-Ozaysal O, Fiche M, Guitierrez M, Wagner KU, Raffoul W, Briskin C. Antagonistic roles of Notch and p63 in controlling mammary epithelial cell fates. *Cell Death Differ*. 2010;17:1600–12.
83. Wang Y, Hayward S, Cao M, Thayer K, Cunha G. Cell differentiation lineage in the prostate. *Differentiation*. 2001;68:270–9.
84. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, et al. p63 is a prostate basal cell marker and is required for prostate development. *Am J Pathol*. 2000;157:1769–75.
85. Huang Y, Hamana T, Liu J, Wang C, An L, You P, et al. Prostate sphere-forming stem cells are derived from the P63-expressing basal compartment. *J Biol Chem*. 2015;290:17745–52.
86. Signoretti S, Loda M. Defining cell lineages in the prostate epithelium. *Cell Cycle*. 2006;5:138–41.
87. Lee DK, Liu Y, Liao L, Wang F, Xu J. The prostate basal cell (BC) heterogeneity and the p63-positive BC differentiation spectrum in mice. *Int J Biol Sci*. 2014;10:1007–17.
88. Signoretti S, Pires MM, Lindauer M, Horner JW, Grisanzio C, Dhar S, et al. p63 regulates commitment to the prostate cell lineage. *Proc Natl Acad Sci USA*. 2005;102:11355–60.
89. Grisanzio C, Signoretti S. p63 in prostate biology and pathology. *J Cell Biochem*. 2008;103:1354–68.
90. Rai S, Alsaïdan OA, Yang H, Cai H, Wang L. Heparan sulfate inhibits transforming growth factor beta signaling and functions in cis and in trans to regulate prostate stem/progenitor cell activities. *Glycobiology*. 2020;30:381–95.
91. Amatu JB, Baudouin C, Trinh L, Labbe A, Buffault J. [Corneal epithelial biomechanics: resistance to stress and role in healing and remodeling]. *J Fr Ophthalmol*. 2023;46:287–99.
92. Tang Q, Luo C, Lu B, Fu Q, Yin H, Qin Z, et al. Thermosensitive chitosan-based hydrogels releasing stromal cell derived factor-1 alpha recruit MSC for corneal epithelium regeneration. *Acta Biomater*. 2017;61:101–13.
93. Sridhar MS. Anatomy of cornea and ocular surface. *Indian J Ophthalmol*. 2018;66:190–4.
94. Arpitha P, Prajna NV, Srinivasan M, Muthukkaruppan V. High expression of p63 combined with a large N/C ratio defines a subset of human limbal epithelial cells: implications on epithelial stem cells. *Invest Ophthalmol Vis Sci*. 2005;46:3631–6.
95. Shalom-Feuerstein R, Lena AM, Zhou H, De La Forest Divonne S, Van Bokhoven H, Candi E, et al. DeltaNp63 is an ectodermal gatekeeper of epidermal morphogenesis. *Cell Death Differ*. 2011;18:887–96.
96. Novelli F, Ganini C, Melino G, Nucci C, Han Y, Shi Y, et al. p63 in corneal and epithelial differentiation. *Biochem Biophys Res Commun*. 2022;610:15–22.
97. Ekpo P, Inthasin N, Matamnan S, Wongprompitak P, Wattananapitch M, Boonwong C, et al. Characterization of limbal explant sites: optimization of stem cell outgrowth in vitro culture. *PLoS ONE*. 2020;15:e0233075.
98. Li Y, Inoue T, Takamatsu F, Kobayashi T, Shiraishi A, Maeda N, et al. Differences between niche cells and limbal stromal cells in maintenance of corneal limbal stem cells. *Invest Ophthalmol Vis Sci*. 2014;55:1453–62.
99. Shaharuddin B, Harvey I, Ahmad S, Ali S, Meeson A. Characterisation of human limbal side population cells isolated using an optimised protocol from an immortalised epithelial cell line and primary limbal cultures. *Stem Cell Rev Rep*. 2014;10:240–50.
100. Jeong WY, Yoo HY, Kim CW. beta-cellulin promotes the proliferation of corneal epithelial stem cells through the phosphorylation of erk1/2. *Biochem Biophys Res Commun*. 2018;496:359–66.
101. Di Iorio E, Barbaro V, Ruzza A, Ponzin D, Pellegrini G, De Luca M. Isoforms of DeltaNp63 and the migration of ocular limbal cells in human corneal regeneration. *Proc Natl Acad Sci USA*. 2005;102:9523–8.
102. Wang DY, Cheng CC, Kao MH, Hsueh YJ, Ma DH, Chen JK. Regulation of limbal keratinocyte proliferation and differentiation by TAp63 and DeltaNp63 transcription factors. *Invest Ophthalmol Vis Sci*. 2005;46:3102–8.
103. Gordon J, Wilson VA, Blair NF, Sheridan J, Farley A, Wilson L, et al. Functional evidence for a single endodermal origin for the thymic epithelium. *Nat Immunol*. 2004;5:546–53.
104. Stefanski HE, Xing Y, Nicholls J, Jonart L, Goren E, Taylor PA, et al. P63 targeted deletion under the FOXN1 promoter disrupts pre-and post-natal thymus development, function and maintenance as well as induces severe hair loss. *PLoS ONE*. 2022;17:e0261770.
105. Di Como CJ, Urist MJ, Babayan I, Drobnyak M, Hedvat CV, Teruya-Feldstein J, et al. p63 expression profiles in human normal and tumor tissues. *Clin Cancer Res*. 2002;8:494–501.
106. Shi Y, Dong M, Zhou Y, Li W, Gao Y, Han L, et al. Distal airway stem cells ameliorate bleomycin-induced pulmonary fibrosis in mice. *Stem Cell Res Ther*. 2019;10:161.
107. Zhou Y, Wang Y, Li D, Zhang T, Ma Y, Zuo W. Stable long-term culture of human distal airway stem cells for transplantation. *Stem Cells Int*. 2021;2021:9974635.
108. Kumar PA, Hu Y, Yamamoto Y, Hoe NB, Wei TS, Mu D, et al. Distal airway stem cells yield alveoli in vitro and during lung regeneration following H1N1 influenza infection. *Cell*. 2011;147:525–38.
109. Xiao Z, Jiang Q, Willette-Brown J, Xi S, Zhu F, Burkett S, et al. The pivotal role of IKKalpha in the development of spontaneous lung squamous cell carcinomas. *Cancer Cell*. 2013;23:527–40.
110. Barkauskas CE, Counce MJ, Rackley CR, Bowie EJ, Keene DR, Stripp BR, et al. Type 2 alveolar cells are stem cells in adult lung. *J Clin Invest*. 2013;123:3025–36.
111. Fernanda de Mello Costa M, Weiner AI, Vaughan AE. Basal-like progenitor cells: a review of dysplastic alveolar regeneration and remodeling in lung repair. *Stem Cell Rep*. 2020;15:1015–25.
112. Peng W, Chang M, Wu Y, Zhu W, Tong L, Zhang G, et al. Lyophilized powder of mesenchymal stem cell supernatant attenuates acute lung injury through the IL-6-p-STAT3-p63-JAG2 pathway. *Stem Cell Res Ther*. 2021;12:216.
113. Arason AJ, Jonsdottir HR, Halldorsson S, Benediktsdottir BE, Bergthorsson JT, Ingthorsson S, et al. deltaNp63 has a role in maintaining epithelial integrity in airway epithelium. *PLoS ONE*. 2014;9:e88683.
114. Tanaka Y, Yamaguchi M, Hirai S, Sumi T, Tada M, Saito A, et al. Characterization of distal airway stem-like cells expressing N-terminally truncated p63 and thyroid transcription factor-1 in the human lung. *Exp Cell Res*. 2018;372:141–9.
115. Weiner AI, Zhao G, Zayas HM, Holcomb NP, Adams-Tzivelekidis S, Wong J, et al. DeltaNp63 drives dysplastic alveolar remodeling and restricts epithelial plasticity upon severe lung injury. *Cell Rep*. 2022;41:111805.
116. Fukumoto J, Sidramagowda Patil S, Krishnamurthy S, Saji S, John I, Narala VR, et al. Altered expression of p63 isoforms and expansion of p63- and club cell secretory protein-positive epithelial cells in the lung as novel features of aging. *Am J Physiol Cell Physiol*. 2019;316:C492–508.
117. Bouras T, Pal B, Vaillant F, Harburg G, Asselin-Labat ML, Oakes SR, et al. Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. *Cell Stem Cell*. 2008;3:429–41.



118. Schroeter EH, Kisslinger JA, Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. *Nature*. 1998;393:382–6.
119. Okuyama R, Ogawa E, Nagoshi H, Yabuki M, Kurihara A, Terui T, et al. p53 homologue, p51/p63, maintains the immaturity of keratinocyte stem cells by inhibiting Notch1 activity. *Oncogene*. 2007;26:4478–88.
120. Koh LF, Ng BK, Bertrand J, Thierry F. Transcriptional control of late differentiation in human keratinocytes by TAp63 and Notch. *Exp Dermatol*. 2015;24:754–60.
121. Tadeu AM, Horsley V. Notch signaling represses p63 expression in the developing surface ectoderm. *Development*. 2013;140:3777–86.
122. Kent S, Hutchinson J, Balboni A, Decastro A, Cherukuri P, Drenzo J. DeltaNp63alpha promotes cellular quiescence via induction and activation of Notch3. *Cell Cycle*. 2011;10:3111–8.
123. Teuliere J, Faraldo MM, Deugnier MA, Shtutman M, Ben-Ze'ev A, Thierry JP, et al. Targeted activation of beta-catenin signaling in basal mammary epithelial cells affects mammary development and leads to hyperplasia. *Development*. 2005;132:267–77.
124. Zhang X, Dong N, Hu X. Wnt/beta-catenin signaling inhibitors. *Curr Top Med Chem*. 2023;23:880–96.
125. Holland JD, Klaus A, Garratt AN, Birchmeier W. Wnt signaling in stem and cancer stem cells. *Curr Opin Cell Biol*. 2013;25:254–64.
126. Zhang Y, Wang X. Targeting the Wnt/beta-catenin signaling pathway in cancer. *J Hematol Oncol*. 2020;13:165.
127. Rim EY, Clevers H, Nusse R. The Wnt pathway: from signaling mechanisms to synthetic modulators. *Annu Rev Biochem*. 2022;91:571–98.
128. Briscoe J, Thérond PP. The mechanisms of Hedgehog signalling and its roles in development and disease. *Nat Rev Mol Cell Biol*. 2013;14:416–29.
129. Sari IN, Phi LTH, Jun N, Wijaya YT, Lee S, Kwon HY. Hedgehog signaling in cancer: a prospective therapeutic target for eradicating cancer stem cells. *Cells*. 2018;7:208.
130. Chari NS, Romano RA, Koster MI, Jaks V, Roop D, Flores ER, et al. Interaction between the TP63 and SHH pathways is an important determinant of epidermal homeostasis. *Cell Death Differ*. 2013;20:1080–8.
131. Li J, Yuan Y, He J, Feng J, Han X, Jing J, et al. Constitutive activation of hedgehog signaling adversely affects epithelial cell fate during palatal fusion. *Dev Biol*. 2018;441:191–203.
132. Girardet L, Cyr DG, Belleanne C. Arl13b controls basal cell stemness properties and Hedgehog signaling in the mouse epididymis. *Cell Mol Life Sci*. 2022;79:556.
133. Candi E, Amelio I, Agostini M, Melino G. MicroRNAs and p63 in epithelial stemness. *Cell Death Differ*. 2015;22:12–21.
134. Suh N. MicroRNA controls of cellular senescence. *BMB Rep*. 2018;51:493–9.
135. Sun L, Zhu W, Zhao P, Zhang J, Lu Y, Zhu Y, et al. Down-regulated exosomal microRNA-221 - 3p derived from senescent mesenchymal stem cells impairs heart repair. *Front Cell Dev Biol*. 2020;8:263.
136. Ortiz GGR, Mohammadi Y, Nazari A, Ataeinaeini M, Kazemi P, Yasamineh S, et al. A state-of-the-art review on the MicroRNAs roles in hematopoietic stem cell aging and longevity. *Cell Commun Signal*. 2023;21:85.
137. Potter ML, Hill WD, Isaacs CM, Hamrick MW, Fulzele S. MicroRNAs are critical regulators of senescence and aging in mesenchymal stem cells. *Bone*. 2021;142:115679.
138. Chen HL, Chiang PC, Lo CH, Lo YH, Hsu DK, Chen HY, et al. Galectin-7 regulates keratinocyte proliferation and differentiation through JNK-miR-203-p63 signaling. *J Invest Dermatol*. 2016;136:182–91.
139. Kim YJ, Lee SB, Lee HB. Oleic acid enhances keratinocytes differentiation via the upregulation of miR-203 in human epidermal keratinocytes. *J Cosmet Dermatol*. 2019;18:383–9.
140. Rivetti di Val Cervo P, Lena AM, Nicoloso M, Rossi S, Mancini M, Zhou H, et al. p63-microRNA feedback in keratinocyte senescence. *Proc Natl Acad Sci USA*. 2012;109:1133–8.
141. Chikh A, Matin RN, Senatore V, Hufbauer M, Lavery D, Raimondi C, et al. iASPP/p63 autoregulatory feedback loop is required for the homeostasis of stratified epithelia. *EMBO J*. 2011;30:4261–73.
142. Panatta E, Lena AM, Mancini M, Smirnov A, Marini A, Delli Ponti R, et al. Long non-coding RNA uc.291 controls epithelial differentiation by interfering with the ACTL6A/BAF complex. *EMBO Rep*. 2020;21:e46734.
143. Kretz M, Siprashvili Z, Chu C, Webster DE, Zehnder A, Qu K, et al. Control of somatic tissue differentiation by the long non-coding RNA TINCR. *Nature*. 2013;493:231–5.
144. Mancini M, Cappello A, Pecorari R, Lena AM, Montanaro M, Fania L, et al. Involvement of transcribed lncRNA uc.291 and SWI/SNF complex in cutaneous squamous cell carcinoma. *Discov Oncol*. 2021;12:14.
145. Ma Y, Di Y, Li Q, Zhan Q, He X, Liu S, et al. lncRNAs as epigenetic regulators of epithelial to mesenchymal transition in pancreatic cancer. *Discov Oncol*. 2022;13:61.
146. Lin Z, Feng F, Liang J, Zeng H, Li J. lncRNA RP11-10A14.5: a potential prognosis biomarker for LUAD through regulation on proliferation and metastasis. *Discov Oncol*. 2022;13:32.
147. Chen Z, Bian C, Huang J, Li X, Chen L, Xie X, et al. Tumor-derived exosomal HOTAIRM1 regulates SPON2 in CAFs to promote progression of lung adenocarcinoma. *Discov Oncol*. 2022;13:92.
148. Wei W, Xu T, Zhang Y, Huang Y, Wang X. Upregulation of long noncoding RNA linc02544 and its association with overall survival rate and the influence on cell proliferation and migration in lung squamous cell carcinoma. *Discov Oncol*. 2022;13:41.
149. Wang J, Li L, Jiang X, Wang B, Hu X, Liu W, et al. Silencing of long non-coding RNA TUC338 inhibits the malignant phenotype of nasopharyngeal cancer cells via modulating the miR-1226-3p/FGF2 axis. *Discov Oncol*. 2022;13:102.
150. Tanis SEJ, Koksal ES, van Buggenum J, Mulder KW. BLNCR is a long non-coding RNA adjacent to integrin beta-1 that is rapidly lost during epidermal progenitor cell differentiation. *Sci Rep*. 2019;9:31.
151. Fierro C, Gatti V, La Banca V, De Domenico S, Scalera S, Corleone G, et al. The long non-coding RNA NEAT1 is a DeltaNp63 target gene modulating epidermal differentiation. *Nat Commun*. 2023;14:3795.
152. Fessing MY, Mardaryev AN, Gdula MR, Sharov AA, Sharova TY, Rapisarda V, et al. p63 regulates Satb1 to control tissue-specific chromatin remodeling during development of the epidermis. *J Cell Biol*. 2011;194:825–39.
153. Rinaldi L, Datta D, Serrat J, Morel L, Solanas G, Avgustinova A, et al. Dnmt3a and Dnmt3b associate with enhancers to regulate human epidermal stem cell homeostasis. *Cell Stem Cell*. 2016;19:491–501.
154. Liu B, Liu YF, Du YR, Mardaryev AN, Yang W, Chen H, et al. Cbx4 regulates the proliferation of thymic epithelial cells and thymus function. *Development*. 2013;140:780–8.
155. Mardaryev AN, Liu B, Rapisarda V, Poterłowicz K, Malashchuk I, Rudolf J, et al. Cbx4 maintains the epithelial lineage identity and cell proliferation in the developing stratified epithelium. *J Cell Biol*. 2016;212:77–89.
156. Carroll DK, Carroll JS, Leong CO, Cheng F, Brown M, Mills AA, et al. p63 regulates an adhesion programme and cell survival in epithelial cells. *Nat Cell Biol*. 2006;8:551–61.
157. Kurata S, Okuyama T, Osada M, Watanabe T, Tomimori Y, Sato S, et al. p51/p63 controls subunit alpha3 of the major epidermis integrin anchoring the stem cells to the niche. *J Biol Chem*. 2004;279:50069–77.
158. Favalaro B, Tamburro A, Angelucci S, Luca AD, Melino S, di Ilio C, et al. Molecular cloning, expression and site-directed mutagenesis of glutathione S-transferase from *Ochrobactrum anthropi*. *Biochem J*. 1998;335:573–9.
159. Yan Y, He M, Zhao L, Wu H, Zhao Y, Han L, et al. A novel HIF-2alpha targeted inhibitor suppresses hypoxia-induced breast cancer stemness via SOD2-mtROS-PDI/GPR78-UPR(ER) axis. *Cell Death Differ*. 2022;29:1769–89.
160. Baumeister R, Murphy CT, Heimbucher T. Metabolic adaptation to hypoxia: do worms and cancer cells share common metabolic responses to hypoxic stress? *Cell Death Differ*. 2021;28:1434–6.
161. Chen J, Liu Y, Zhao Z, Qiu J. Oxidative stress in the skin: impact and related protection. *Int J Cosmet Sci*. 2021;43:495–509.
162. Liu HM, Cheng MY, Xun MH, Zhao ZW, Zhang Y, Tang W, et al. Possible mechanisms of oxidative stress-induced skin cellular senescence, inflammation, and cancer and the therapeutic potential of plant polyphenols. *Int J Mol Sci*. 2023;24:3755.
163. Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Beppu H, Minda K, et al. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. *Mol Cell*. 2002;10:995–1005.
164. Amelio I, Melino G, Candi E. p63 adjusts sugar taste of epidermal layers. *J Invest Dermatol*. 2017;137:1204–6.
165. Hamanaka RB, Mutlu GM. PFKFB3, a direct target of p63, is required for proliferation and inhibits differentiation in epidermal keratinocytes. *J Invest Dermatol*. 2017;137:1267–76.
166. Smirnov A, Lena AM, Cappello A, Panatta E, Anemona L, Bischetti S, et al. ZNF185 is a p63 target gene critical for epidermal differentiation and squamous cell carcinoma development. *Oncogene*. 2019;38:1625–38.
167. Choo MK, Kraft S, Missero C, Park JM. The protein kinase p38alpha destabilizes p63 to limit epidermal stem cell frequency and tumorigenic potential. *Sci Signal*. 2018;11:eaau0727.
168. Wu L, Chen X, Zhao J, Martin B, Zepp JA, Ko JS, et al. A novel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4-ERK5 axis. *J Exp Med*. 2015;212:1571–87.
169. Gatti V, Fierro C, Compagnone M, La Banca V, Mauriello A, Montanaro M, et al. DeltaNp63-Senataxin circuit controls keratinocyte differentiation by promoting the transcriptional termination of epidermal genes. *Proc Natl Acad Sci USA*. 2022;119:e2104718119.
170. Conforti F, Yang AL, Piro MC, Mellone M, Terrinoni A, Candi E, et al. PIR2/Rnf144B regulates epithelial homeostasis by mediating degradation of p21WAF1 and p63. *Oncogene*. 2013;32:4758–65.
171. Balboni AL, Hutchinson JA, DeCastro AJ, Cherukuri P, Liby K, Sporn MB, et al. DeltaNp63alpha-mediated activation of bone morphogenetic protein signaling



- governs stem cell activity and plasticity in normal and malignant mammary epithelial cells. *Cancer Res.* 2013;73:1020–30.
172. Candi E, Terrinoni A, Rufini A, Chikh A, Lena AM, Suzuki Y, et al. p63 is upstream of IKK alpha in epidermal development. *J Cell Sci.* 2006;119:4617–22.
  173. Orzoi P, Holcakova J, Nekulova M, Nenutil R, Vojtesek B, Coates PJ. The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site. *Histol Histopathol.* 2015;30:503–21.
  174. Fisher ML, Balinth S, Mills AA. DeltaNp63alpha in cancer: importance and therapeutic opportunities. *Trends Cell Biol.* 2022;33:280–92.
  175. Gatti V, Bongiorno-Borbone L, Fierro C, Annicchiarico-Petruzzelli M, Melino G, Peschiaroli A. p63 at the crossroads between stemness and metastasis in breast cancer. *Int J Mol Sci.* 2019;20:2683.
  176. Massion PP, Tafian PM, Rahman SM, Yildiz P, Shyr Y, Carbone DP, et al. Role of p63 amplification and overexpression in lung cancer development. *Chest.* 2004;125:1025.
  177. Botchkarev VA, Flores ER. p53/p63/p73 in the epidermis in health and disease. *Cold Spring Harb Perspect Med.* 2014;4:a015248.
  178. Gonfloni S, Caputo V, Iannizzotto V. P63 in health and cancer. *Int J Dev Biol.* 2015;59:87–93.
  179. Verma P, Shukla N, Kumari S, Ansari MS, Gautam NK, Patel GK. Cancer stem cell in prostate cancer progression, metastasis and therapy resistance. *Biochim Biophys Acta Rev Cancer.* 2023;1878:188887.
  180. Qureshi-Baig K, Ullmann P, Haan S, Letellier E. Tumor-initiating cells: a critical review of isolation approaches and new challenges in targeting strategies. *Mol Cancer.* 2017;16:40.
  181. Chaudhary A, Raza SS, Haque R. Transcriptional factors targeting in cancer stem cells for tumor modulation. *Semin Cancer Biol.* 2023;88:123–37.
  182. Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. *Nat Rev Cancer.* 2012;12:133–43.
  183. Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. *Cell Stem Cell.* 2012;10:717–28.
  184. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. *Cancer Cell.* 2012;21:283–96.
  185. McMullen JRW, Soto U. Newly identified breast luminal progenitor and gestational stem cell populations likely give rise to HER2-overexpressing and basal-like breast cancers. *Discov Oncol.* 2022;13:38.
  186. Nagao K, Kato C, Ikemoto Y, Motojima T, Fujii K, Umezawa A, et al. PTC1-null induced pluripotent stem cells exclusively differentiate into immature ectodermal cells with large areas of medulloblastoma-like tissue. *Discov Oncol.* 2022;13:36.
  187. Memmi EM, Sanarico AG, Giacobbe A, Peschiaroli A, Frezza V, Cicalese A, et al. p63 sustains self-renewal of mammary cancer stem cells through regulation of Sonic Hedgehog signaling. *Proc Natl Acad Sci USA.* 2015;112:3499–504.
  188. Du Z, Li J, Wang L, Bian C, Wang Q, Liao L, et al. Overexpression of DeltaNp63alpha induces a stem cell phenotype in MCF7 breast carcinoma cell line through the Notch pathway. *Cancer Sci.* 2010;101:2417–24.
  189. Boldrup L, Coates PJ, Gu X, Nylander K. DeltaNp63 isoforms regulate CD44 and keratins 4, 6, 14 and 19 in squamous cell carcinoma of head and neck. *J Pathol.* 2007;213:384–91.
  190. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. *Proc Natl Acad Sci USA.* 2007;104:973–8.
  191. Ferronika P, Triningsih FX, Ghozali A, Moeljono A, Rahmayanti S, Shadrina AN, et al. p63 cytoplasmic aberrance is associated with high prostate cancer stem cell expression. *Asian Pac J Cancer Prev.* 2012;13:1943–8.
  192. Su X, Napoli M, Abbas HA, Venkatanarayan A, Bui NHB, Coarfa C, et al. TAp63 suppresses mammary tumorigenesis through regulation of the Hippo pathway. *Oncogene.* 2017;36:2377–93.
  193. Keyes WM, Pecoraro M, Aranda V, Vernersson-Lindahl E, Li W, Vogel H, et al. DeltaNp63alpha is an oncogene that targets chromatin remodeler Lsh to drive skin stem cell proliferation and tumorigenesis. *Cell Stem Cell.* 2011;8:164–76.
  194. Balinth S, Fisher ML, Hwangbo Y, Wu C, Ballon C, Sun X, et al. EZH2 regulates a SETDB1/DeltaNp63alpha axis via RUNX3 to drive a cancer stem cell phenotype in squamous cell carcinoma. *Oncogene.* 2022;41:4130–44.
  195. Wei S, Li J, Tang M, Zhang K, Gao X, Fang L, et al. STAT3 and p63 in the regulation of cancer stemness. *Front Genet.* 2022;13:909251.
  196. Ripamonti F, Albano L, Rossini A, Borrelli S, Fabris S, Mantovani R, et al. EGFR through STAT3 modulates DeltaN63alpha expression to sustain tumor-initiating cell proliferation in squamous cell carcinomas. *J Cell Physiol.* 2013;228:871–8.
  197. Galoczova M, Coates P, Vojtesek B. STAT3, stem cells, cancer stem cells and p63. *Cell Mol Biol Lett.* 2018;23:12.
  198. Saladi SV, Ross K, Karaayvaz M, Tata PR, Mou H, Rajagopal J, et al. ACTL6A is co-amplified with p63 in squamous cell carcinoma to drive YAP activation, regenerative proliferation, and poor prognosis. *Cancer Cell.* 2017;31:35–49.
  199. Fisher ML, Kerr C, Adhikary G, Grun D, Xu W, Keillor JW, et al. Transglutaminase interaction with alpha6/beta4-integrin stimulates YAP1-dependent DeltaNp63alpha stabilization and leads to enhanced cancer stem cell survival and tumor formation. *Cancer Res.* 2016;76:7265–76.
  200. Li MY, Fan LN, Han DH, Yu Z, Ma J, Liu YX, et al. Ribosomal S6 protein kinase 4 promotes radioresistance in esophageal squamous cell carcinoma. *J Clin Invest.* 2020;130:4301–19.
  201. Napoli M, Wu SJ, Gore BL, Abbas HA, Lee K, Checker R, et al. DeltaNp63 regulates a common landscape of enhancer associated genes in non-small cell lung cancer. *Nat Commun.* 2022;13:614.
  202. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. *Cell.* 2009;137:87–98.
  203. Kehrlouess S, Osterburg C, Tuppi M, Schafer B, Vousden KH, Dotsch V. Intrinsic aggregation propensity of the p63 and p73 TI domains correlates with p53R175H interaction and suggests further significance of aggregation events in the p53 family. *Cell Death Differ.* 2016;23:1952–60.
  204. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. *Genes Dev.* 2012;26:1268–86.
  205. Neilsen PM, Noll JE, Suetani RJ, Schulz RB, Al-Ejeh F, Evdokiou A, et al. Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. *Oncotarget.* 2011;2:1203–17.
  206. Zhang J, Sun W, Kong X, Zhang Y, Yang HJ, Ren C, et al. Mutant p53 antagonizes p63/p73-mediated tumor suppression via Notch1. *Proc Natl Acad Sci USA.* 2019;116:24259–67.
  207. Gong L, Pan X, Lim CB, de Polo A, Little JB, Yuan ZM. A functional interplay between Delta13p53 and DeltaNp63 in promoting glycolytic metabolism to fuel cancer cell proliferation. *Oncogene.* 2018;37:2150–64.
  208. Lambert AW, Fiore C, Chutake Y, Verhaar ER, Strasser PC, Chen MW, et al. DeltaNp63/p73 drive metastatic colonization by controlling a regenerative epithelial stem cell program in quasi-mesenchymal cancer stem cells. *Dev Cell.* 2022;57:2714–30.e2718.
  209. Lodillinsky C, Infante E, Guichard A, Chaligne R, Fuhrmann L, Cytra J, et al. p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer. *Oncogene.* 2016;35:344–57.
  210. Ganini C, Amelio I, Bertolo R, Bove P, Buonomo OC, Candi E, et al. Global mapping of cancers: The Cancer Genome Atlas and beyond. *Mol Oncol.* 2021;15:2823–40.
  211. Vasilaki E, Morikawa M, Koinuma D, Mizutani A, Hirano Y, Ehata S, et al. Ras and TGF-beta signaling enhance cancer progression by promoting the DeltaNp63 transcriptional program. *Sci Signal.* 2016;9:ra84.
  212. Galoczova M, Nenutil R, Pokorna Z, Vojtesek B, Coates PJ. TAp63 and DeltaNp63 (p40) in prostate adenocarcinomas: DeltaNp63 associates with a basal-like cancer stem cell population but not with metastasis. *Virchows Arch.* 2021;478:627–36.
  213. Truong AB, Kretz M, Ridky TW, Kimmel R, Khavari PA. p63 regulates proliferation and differentiation of developmentally mature keratinocytes. *Genes Dev.* 2006;20:3185–97.
  214. Park E, Kim H, Kim JM, Primack B, Vidal-Cardenas S, Xu Y, et al. FANCD2 activates transcription of TAp63 and suppresses tumorigenesis. *Mol Cell.* 2013;50:908–18.
  215. Xu Y, Yang X, Xiong Q, Han J, Zhu Q. The dual role of p63 in cancer. *Front Oncol.* 2023;13:1116061.
  216. Fisher ML, Balinth S, Mills AA. DeltaNp63alpha in cancer: importance and therapeutic opportunities. *Trends Cell Biol.* 2023;33:280–92.

## ACKNOWLEDGEMENTS

The authors thank Richard Knight for helpful and constructive criticisms. All the figures except Fig. 1 were prepared using the BioRender online website (<https://www.biorender.com>).

## AUTHOR CONTRIBUTIONS

EC, YS, FB, and GM conceived the project; YL prepared the first draft; YL, SG, TW, JF, PL, CS, EC, YS, GM, and FB wrote the manuscript; YL prepared figures. All of the Authors have approved this submitted version.

## FUNDING

This work has been supported by the MUR-PNRR M4C211.3 PE6 project PE00000019 Heal Italia (CUP: E83C22004670001) to FB, GM, EC, MA, MF, MP. The Research leading to these results has received funding from AIRC under IG 2019 – 23232 – P.I. Bernassola Francesca, under IG 2022 – ID. 27366 project – P.I. Melino Gennaro, under IG 2019 – ID. 22206 – P.I. Candi Eleonora. Work has been also partially supported by

Fondazione Luigi Maria Monti IDI-IRCCS (R.C. to EC) and by Regione Lazio through LaziolInnova Progetto Gruppo di Ricerca n 85-2017-14986; n 33 & 55-2021-T0002E0001.

### COMPETING INTERESTS

GM and YS are members of the Editorial Board of *Oncogene*. The authors declare no competing interests.

### ADDITIONAL INFORMATION

**Correspondence** and requests for materials should be addressed to Yufang Shi, Eleonora Candi, Gerry Melino or Francesca Bernassola.

**Reprints and permission information** is available at <http://www.nature.com/reprints>

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

### TOR CENTRE

Massimiliano Agostini<sup>1</sup>, Pierluigi Bove<sup>1</sup>, Alessandro Mauriello<sup>1</sup>, Giuseppe Novelli<sup>5</sup>, Mauro Piacentini<sup>6</sup>, Valentina Rovella<sup>1</sup>, Manuel Scimeca<sup>1</sup>, Giuseppe Sica<sup>1</sup>, Qiang Sun<sup>7</sup> and Giuseppe Tisone<sup>1</sup>

<sup>5</sup>Dipartimento di Biomedicina e prevenzione, University of Rome Tor Vergata, 00133 Rome, Italy. <sup>6</sup>Department of Biology, University of Rome Tor Vergata, 00133 Rome, Italy.

<sup>7</sup>Chinese Academy of Medical Science, Beijing 100071, China.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023